Clinical trials: Former Smokers
- Condition Former Smokers
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Smoking Cessation
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data…
- Trial name
- CATS (NCT01574703)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 134 sites in United States, Argentina and 14 more
- Volunteers
- 4,595 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cigarette Smoking
A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation
The purpose of this study was to understand the biological and functional changes after one year of smoking cessation and to collect data on a broad range of biomarkers of exposure (BoExp) and biomarkers of effect (BoE).
- Trial name
- RIBESC (NCT02432729)
- Where
- 5 sites in United States, Germany and 3 more
- Volunteers
- 1,184 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in Denmark
Real life smoking cessation rates after 24 weeks non-intervention design. Approximately 40 General Practice (GP) centers with 800 smokers will participate.
- Trial name
- ESCAPE SMOKE (NCT01544621)
- Testing
- Smoking cessation
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Disorders
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
The purpose of this study is to test two different vaccine schedules to be used for administering the investigational NTHi Mcat vaccine that will be targeting patients with chronic obstructive pulmonary disease (COPD) to prevent…
- Trial name
- NCT03443427
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 8 sites in Canada, Germany and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation, Insurance Coverage
Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
This study is based on the hypothesis that access to smoking cessation treatment (SCT) reimbursement may significantly increase the number of successful quitters in a population of smokers motivated to quit by: 1) increasing the…
- Trial name
- ACCESSATION (NCT00818207)
- Testing
- Full Smoking Cessation Treatment Coverage (100%), No Smoking Cessation Treatment Coverage (0%)
- Where
- 56 sites in Canada
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD, Asthma
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
This study will collect sputum samples from healthy smokers, COPD smokers and COPD ex-smokers to analyse biomarkers of inflammation
- Trial name
- NCT02490358
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Respiratory Disorders
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of 8 different formulations of investigational NTHI vaccine in current and former smokers, 50-70 years of age.
- Trial name
- NCT01678677
- Testing
- NTHI vaccine GSK2838500A (formulation 1), NTHI vaccine GSK2838501A (formulation 2), NTHI vaccine GSK2838502A (formulation 3)
- Where
- 3 sites in Belgium
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline